Incidence and predictors of cytomegalovirus pneumonia in orthotopic liver transplant recipients

Transplantation

Volumn 61, Issue 12, 1996, Pages 1716-1720

  Falagas, Matthew E ^a,b   Snydman, David R ^a,b   George, Marie J ^a,b   Werner, Barbara ^a,f   Ruthazer, Robin ^a   Griffith, John ^a,b   Rohrer, Richard H ^a,b   Freeman, Richard ^a,b   Fawaz, Karim ^a,b   Hoffman, Mark A ^a,b   Kaplan, Marshall ^a,b   Gill, Maura ^a,b   Rubin, Robert H ^a,c   Dienstag, Jules L ^a,c   Doran, Maureen ^a,c   O'Rourke, Edward ^a,d   Vacanti, Joseph ^a,d   Jenkins, Roger ^a,e   Lewis, W David ^a,e   Hammer, Scott ^a,e   Martin, Maureen ^a,e   Fairchild, Ralph ^a,e   Grady, George F ^a,f   Leszczynski, Jeanne ^a,f   Dougherty, Nancy ^a,f   Katz, Andrea ^a,f   Fausett, Gary ^a,f   Platt, Richard ^a,g   Cheeseman, Sarah H ^a,g   Pasternack, Mark ^a,g   Gorbach, Sherwood L ^a,g   more..

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d Children's Hospital

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^f Massachusetts State Laboratory   (United States)

^g Massachusetts State Lab Institute ^*

Author keywords

[No Author keywords available]

Indexed keywords

CYTOMEGALOVIRUS ANTIBODY; METHYLPREDNISOLONE SODIUM SUCCINATE; OKT 3; THYMOCYTE ANTIBODY;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; GRAFT REJECTION; HUMAN; INCIDENCE; INFECTION PREVENTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MORTALITY; MULTICENTER STUDY; PNEUMONIA; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROLOGY; VIREMIA;

ADULT; ANALYSIS OF VARIANCE; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULINS; INCIDENCE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PNEUMONIA, VIRAL; POSTOPERATIVE COMPLICATIONS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 8944245854     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199606270-00009     Document Type: Article

References (31)

1. Rubin RH. Infection in the organ transplant recipient. In: Rubin RH, Young LS, eds. Clinical approach to infection in the compromised host. 3rd ed. New York: Plenum, 1994: 629.
2. Snydman DR, Werner BG, Griffith J. Role of cytomegalovirus (CMV) disease in mortality of orthotopic liver transplant (OLT) recipients. [Abstract]. New Orleans: 33rd International Congress of Antimicrobial Agents and Chemotherapy, 1993: 1202.
3. Stratta RJ, Shaefer MS, Markin RS, et al. Clinical patterns of cytomegalovirus disease after liver transplantation. Arch Surg 1989; 124: 1443.
4. Wiesner RH, Marin E, Porayko MK, Steers JL, Krom RAF, Paya CV. Advances in liver transplantation. Gastroenterol Clin North Am 1993; 22: 351.
5. Hadley S, Samore MH, Lewis DW, Jenkins RL, Karchmer AW, Hammer SM. Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or FK506 as primary immunosuppression. Transplantation 1995; 59: 851.
6. Paya CV, Hermans PE, Wiesner RH, et al. Cytomegalovirus hepatitis in liver transplantation: prospective analysis of 93 consecutive orthotopic liver transplantations. J Infect Dis 1989; 160: 752.
7. Manez R, Kusne S, Martin M, et al. The impact of blood transfusion on the occurrence of pneumonitis in primary cytomegalovirus infection after liver transplantation. Transfusion 1993; 33: 594.
8. Afessa B, Gay PC, Plevak DJ, Swensen SJ, Patel HG, Krowka MJ. Pulmonary complications of orthotopic liver transplantation. Mayo Clin Proc 1993; 68: 427.
9. Lauchart W. Incidence, prevention and therapy of cytomegalovirus and Pneumocystis carinii pneumonia after liver transplantation. Medizin Klinik 1992; 87 (Suppl 1): 60.
10. Snydman DR, Werner BG, Dougherty NN, et al. Cytomegalovirus immune globulin prophylaxis in liver transplantation. Ann Intern Med 1993; 119: 984.
11. Arbo MD, Snydman DR. Influence of blood culture results on antibiotic choice in the treatment of bacteremia. Arch Intern Med 1994; 154: 2641.
12. Paya CV, Wiesner RH, Hermans PE, et al. Risk factors for cytomegalovirus and severe bacterial infections following liver transplantation: a prospective multivariate time-dependent analysis. J Hepatol 1993; 18: 185.
13. Winston DJ, Wirin D, Shaked A, Busuttil RW. Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients. Lancet 1995; 346: 69.
14. Pillay D, Charman H, Burroughs AD, Smith M, Rolles K, Griffiths PD. Surveillance for CMV infection in orthotopic liver transplant recipients. Transplantation 1992; 53: 1261.
15. Stratta RJ, Shaeffer MS, Markin RS, et al. Cytomegalovirus infection and disease after liver transplantation. An overview. Digest Dis Sci 1992; 37: 673.
16. SAS/STAT User's Guide, version 6, 4th ed. Cary, NC: SAS Institute Inc., 1990.
17. Ettinger NA, Bailey TC, Trulock EP, et al. Cytomegalovirus infection and pneumonitis. Impact after isolated lung transplantation. Am Rev Respir Dis 1993; 147: 1017.
18. George MJ, Snydman DR, Werner BG, et al. Cytomegalovirus disease as a risk factor for fungal disease in orthotopic liver transplant recipients. [Abstract]. Anaheim: 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, 1992:32.
19. Falagas ME, Snydman DR, Griffith J, Werner B, and CMVIG Study Group. CMV exposure from the donated organ is a risk factor for bacteremia in orthotopic liver transplant recipients. [Abstract]. San Francisco: 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1995: 377.
20. Collins LA, Samore MH, Roberts MS, et al. Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J Inf Dis 1994; 170: 644.
21. Schooley RT, Hirsch MS, Colvin RB, et al. Association of herpesvirus infections with T-lymphocyte subset alterations, glomerulopathy, and opportunistic infections after renal transplantation. N Engl J Med 1983; 308: 307.
22. Hamilton JR, Overll JC, Glascow LA. Synergistic effect on mortality in mice with murine Cytomegalovirus and Pseudomonas aeruginosa, Staphylococcus aureus, or Candida albicans infections. Infect Immunol 1976; 14: 982.
23. Granowitz EV, Santos AA, Poutsiaka DD, et al. Production of interleukin-1-receptor antagonist during experimental endotoxemia. Lancet 1991; 338: 1423.
24. Shapiro L, Clark BD, Orencole SF, Poutsiaka DD, Granowitz EV, Dinarello CA. Detection of tumor necrosis factor soluble receptor p55 in blood samples from healthy and endotoxemic humans. J Infect Dis 1993; 167: 1344.
25. Dummer JS, White LT, Ho M, Griffith BP, Hardesty RL, Bahnson HT. Morbidity of cytomegalovirus infection in heart or heart-lung transplants who received cyclosporine. J Infect Dis 1985; 152: 1182.
26. Schulman LL, Reison DS, Austin JH, Rose EA. Cytomegalovirus pneumonitis after cardiac transplantation. Arch Intern Med 1991; 151: 1118.
27. Duncan SR, Cook DJ. Survival of ganciclovir-treated heart transplant recipients with cytomegalovirus pneumonitis. Transplantation 1991; 52: 910.
28. George MJ, Snydman DR, Werner BG, et al. Use of ganciclovir plus cytomegalovirus immune globulin to treat CMV pneumonia in orthotopic transplant recipients. Transplant Proc 1993; 25(suppl 4): 22.
29. Reed EC, Bowden RA, Dandliker PS, Lilleby KE, Meyers JD. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplant. Ann Intern Med 1988; 109: 783.
30. Emanuel D. Treatment of cytomegalovirus disease. Semin Hematol 1990; 27 (suppl 1): 22; discussion 28.
31. Stals FS, Wagenaar SS, Bruggeman CA. Generalized cytomegalovirus (CMV) infection and CMV-induced pneumonitis in the rat: combined effect of 9-(1,3-dihydroxy-2-propoxymethyl) guanine and specific antibody treatment. Antiviral Res 1994; 25: 147.